JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

Search

Becton Dickinson and Co

Uždarymo kaina

SektoriusSveikatos priežiūra

185.78 1.25

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

185.31

Max

185.87

Pagrindiniai rodikliai

By Trading Economics

Pajamos

27M

330M

Pardavimai

104M

5.3B

P/E

Sektoriaus vid.

33.913

38.156

Pelnas, tenkantis vienai akcijai

3.35

Dividendų pajamingumas

2.23

Pelno marža

6.259

Darbuotojai

70,000

EBITDA

93M

546M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+8.32% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

2.23%

2.50%

Kitas uždarbis

2025-08-07

Kitas dividendų mokėjimo data

2025-09-30

Kita Ex Dividend data

2025-09-08

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-15B

50B

Ankstesnė atidarymo kaina

184.53

Ankstesnė uždarymo kaina

185.78

Naujienos nuotaikos

By Acuity

16%

84%

20 / 375 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Becton Dickinson and Co Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-14 14:26; UTC

Įsigijimai, susijungimai, perėmimai

Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5 Billion Deal -- 2nd Update

2025-07-14 11:08; UTC

Įsigijimai, susijungimai, perėmimai

Becton Dickinson Unit to Combine With Waters Corp. in $17.5 Billion Deal -- Update

2025-07-14 10:37; UTC

Įsigijimai, susijungimai, perėmimai

Becton Dickinson Unit to Combine With Waters Corp. in $17.5 Billion Deal

2025-05-01 11:18; UTC

Uždarbis

Becton 2Q Net Down, Warns of Tariff Hit on 2025 EPS

2025-07-15 18:32; UTC

Įsigijimai, susijungimai, perėmimai

Waters Corp. Deal for Becton Dickinson Unit a Long-Term Play With Some Risks -- Analysis

2025-07-15 18:31; UTC

Įsigijimai, susijungimai, perėmimai

Waters Deal for Becton Unit Pairs Near-Term Risks With Possible Long-Term Rewards, Analysts Say

2025-07-14 16:12; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

2025-07-14 15:06; UTC

Įsigijimai, susijungimai, perėmimai

Waters Stock Is Falling on Deal to Combine With Becton Dickinson Unit -- Barrons.com

2025-07-14 14:11; UTC

Įsigijimai, susijungimai, perėmimai

Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5B Deal -- 2nd Update

2025-07-14 10:53; UTC

Įsigijimai, susijungimai, perėmimai

Becton Dickinson Unit to Combine With Waters Corp. in $17.5B Deal -- Update

2025-07-14 10:22; UTC

Įsigijimai, susijungimai, perėmimai

Becton Dickinson Unit to Combine With Waters Corp. in $17.5B Deal

2025-07-14 10:22; UTC

Įsigijimai, susijungimai, perėmimai

Waters To Assume About $4 Billion Incremental Debt >WAT BDX

2025-07-14 10:22; UTC

Įsigijimai, susijungimai, perėmimai

Becton Dickinson to Get $4 Billion Cash Distribution Prior to Closing >WAT BDX

2025-07-14 10:21; UTC

Įsigijimai, susijungimai, perėmimai

Waters Holders to Own 60.8% of Combined Company, Becton Dickinson Holders to Own 39.2% >WAT BDX

2025-07-14 10:20; UTC

Įsigijimai, susijungimai, perėmimai

Waters, Becton Dickinson: Combined Company to Have About $9 Billion Revenue, $3.3 Billion Adjusted Ebitda >WAT

2025-07-14 10:19; UTC

Įsigijimai, susijungimai, perėmimai

Correct: Waters, Becton Dickinson See About $290 Million Revenue Synergies by Year Five >WAT BDX

2025-07-14 10:19; UTC

Įsigijimai, susijungimai, perėmimai

Waters, Becton Dickinson See About $345 Million Annualized Ebitda Synergies by 2030 >WAT BDX

2025-07-14 10:18; UTC

Įsigijimai, susijungimai, perėmimai

Waters, Becton Dickinson See About $290 Revenue Cost Synergies by Year Five >WAT BDX

2025-07-14 10:18; UTC

Įsigijimai, susijungimai, perėmimai

Waters, Becton Dickinson See About $200 Million Cost Synergies by Year Three >WAT BDX

2025-07-14 10:17; UTC

Įsigijimai, susijungimai, perėmimai

Waters: Becton Dickinson Deal Doubles Total Addressable Market to About $40 Billion >WAT

2025-07-14 10:16; UTC

Įsigijimai, susijungimai, perėmimai

Waters, Becton Dickinson Deal Structured as Reverse Morris Trust >WAT BDX

2025-07-14 10:16; UTC

Įsigijimai, susijungimai, perėmimai

Waters, Becton Dickinson Deal Valued at About $17.5 Billion >WAT BDX

2025-07-14 10:15; UTC

Įsigijimai, susijungimai, perėmimai

Waters to Combine With Becton Dickinson's Biosciences & Diagnostic Solutions Business >WAT BDX

2025-07-14 10:15; UTC

Įsigijimai, susijungimai, perėmimai

Waters and BD's Biosciences & Diagnostic Solutions Business to Combine

2025-05-01 10:33; UTC

Uždarbis

Becton Dickinson Cuts FY25 Adj EPS View on Tariff Impact

2025-05-01 10:33; UTC

Uždarbis

Becton Dickinson FY25 Adj EPS View Includes an Estimated Tariff Impact of Approximately 25c

2025-05-01 10:32; UTC

Uždarbis

Becton Dickinson Sees FY25 Organic Rev Growth Guidance of 3.0% to 3.5% >BDX

2025-05-01 10:32; UTC

Uždarbis

Becton Dickinson Narrows FY25 View To Rev $21.8B-$21.9B >BDX

2025-05-01 10:31; UTC

Uždarbis

Becton Dickinson Intends To Invest $2.5 B in U.S. Manufacturing Capacity Over the Next 5 Years >BDX

2025-05-01 10:31; UTC

Uždarbis

Becton Dickinson: Taking 'Decisive Mitigation Actions to Navigate the Current Macro Environment' >BDX

Akcijų palyginimas

Kainos pokytis

Becton Dickinson and Co Prognozė

Kainos tikslas

By TipRanks

8.32% į viršų

12 mėnesių prognozė

Vidutinis 200.73 USD  8.32%

Aukščiausias 255 USD

Žemiausias 172 USD

Remiantis 13 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Becton Dickinson and Co kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

13 ratings

4

Pirkti

9

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

167 / 206.99Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Weak Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Rinkos nuotaikos

By Acuity

20 / 375 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.